1 utcome was the proportion of patients with
a CIDP relapse or who were withdrawn for any other reason
2 patients with IgM monoclonal antibodies
and CIDP reacted to an epitope spanning aa 301-314 of beta-t
3 f the immune attack in patients with GBS
and CIDP.
4 icipate in the pathologic process of GBS
and CIDP.
5 In Guillain-Barre syndrome
and CIDP intravenous immunoglobulin is equivalent to but mor
6 his study, the largest reported trial of
any CIDP treatment, shows the short-term and long-term effic
7 ncern for the clinician when misdiagnosed
as CIDP, in view of the therapeutic implications.
8 mmatory demyelinating polyneuropathy (
CIDP),
CIDP associated with human immunodeficiency virus infect
9 eflect the different pathophysiology of
each CIDP subtype.
10 Recent trials for other agents
for CIDP treatment have not proved as promising, with a larg
11 and individualised treatment strategies
for CIDP.
12 and supports use of IGIV-C as a therapy
for CIDP.
13 g can be used as a maintenance treatment
for CIDP.
14 the use of IVIG (Gamunex) as a treatment
for CIDP.
15 ssays, we showed that the IgGs from the
four CIDP patients prevented adhesive interaction between con
16 tributes that might differentiate POEMS
from CIDP and lead to earlier therapeutic intervention were e
17 cificity of 77% in discriminating POEMS
from CIDP.
18 e was a striking synchronization between
her CIDP and vestibulopathy with respect to clinical course
19 However, in CIDP and
HIV-
CIDP, but not the other diseases, there was prominent up
20 human immunodeficiency virus infection (
HIV-
CIDP), IgM paraproteinaemic neuropathy and normal or non
21 Corticosteroid treatment is beneficial
in CIDP, but not in Guillain-Barre syndrome and may worsen
22 However,
in CIDP and HIV-CIDP, but not the other diseases, there was
23 that these ligands were upregulated only
in CIDP.
24 with the Medical Research Council scale,
in CIDP (rho=0.88, p<0.001) and also in CMT1A (rho=0.50, p<
25 A-DR antigen, the findings indicate that,
in CIDP, Schwann cells possess the necessary markers to fun
26 and the heterogeneous response to therapy
in CIDP.
27 138 POEMS patients and 69
matched CIDP controls were compared.
28 from 1960 to 2007 were compared with
matched CIDP controls.
29 Demyelinating
neuropathy (
CIDP or MMN) occurred in close to 30% of the patients, i
30 patients's relapsing and remitting course
of CIDP and vestibulopathy was assessed by quantitative mus
31 umoral immune systems in the pathogenesis
of CIDP will be discussed.
32 tion) along the nerve where the pathology
of CIDP is probably predominantly proximal and distal.
33 We examined the reactivity
of CIDP patients' sera against neuronal antigens and used i
34 paranodes may participate in the severity
of CIDP.
35 According to the clinical subtype
of CIDP, typical CIDP patients showed symmetric and root-do
36 While the abiding theory
of CIDP pathogenesis is that cell-mediated and humoral mech
37 s immunoglobulin (IVIG) for the treatment
of CIDP and the US Food and Drug Administration approved th
38 ch is to our knowledge, the largest trial
of CIDP to date and the first to study two administrations
39 iously been investigated in a large trial
of CIDP.
40 No
other CIDP patient or any of the 104 controls with other neuro
41 c inflammatory demyelinating
polyneuropathy (
CIDP) are conditions that affect peripheral nerves.
42 c inflammatory demyelinating
polyneuropathy (
CIDP) has occasionally been associated with clinical or
43 c inflammatory demyelinating
polyneuropathy (
CIDP) need long-term intravenous immunoglobulin.
44 c inflammatory demyelinating
polyneuropathy (
CIDP) were compared with 10 healthy subjects.
45 c inflammatory demyelinating
polyneuropathy (
CIDP), CIDP associated with human immunodeficiency virus
46 c inflammatory demyelinating
polyneuropathy (
CIDP), magnetic resonance neurography with 3-dimensional
47 c inflammatory demyelinating
polyneuropathy (
CIDP).
48 c inflammatory demyelinating
polyneuropathy (
CIDP).
49 c inflammatory demyelinating
polyneuropathy (
CIDP).
50 c inflammatory demyelinating
polyneuropathy (
CIDP).
51 matory demyelinating
polyradiculoneuropathy (
CIDP) and multifocal motor neuropathy with conduction bl
52 matory demyelinating
polyradiculoneuropathy (
CIDP) but long-term effects have not been shown.
53 matory demyelinating
polyradiculoneuropathy (
CIDP) is a frequent autoimmune neuropathy with a heterog
54 matory demyelinating
polyradiculoneuropathy (
CIDP) is an inflammatory neuropathy, classically charact
55 matory demyelinating
polyradiculoneuropathy (
CIDP) shows autoantibodies to contactin (1).
56 matory demyelinating
polyradiculoneuropathy (
CIDP), will be discussed.
57 matory demyelinating
polyradiculoneuropathy (
CIDP).
58 Adults with definite or
probable CIDP who responded to intravenous immunoglobulin treatme
59 re many phenotypic variants, suggesting
that CIDP may not be a discrete disease entity but rather a s
60 relationship of cranial nerve involvement
to CIDP remains unclear.
61 ing to the clinical subtype of CIDP,
typical CIDP patients showed symmetric and root-dominant hypertr
62 41.5(10.6) p.u. (CMT1A) and 39.3(8.7) p.
u. (
CIDP).
63 Compared
with CIDP controls, POEMS patients demonstrated: (1) greater
64 Compared
with CIDP, there is greater axonal loss (reduction of motor a
65 Four of 46 sera from patients
with CIDP reacted strongly against hippocampal neurons (8.6%)
66 117 patients
with CIDP who met specific neurophysiological inflammatory ne
67 1 complex occur in a subset of patients
with CIDP who share common clinical features.
68 lemtuzumab) showing benefit in patients
with CIDP, but the side effect profiles can be worrisome.
69 -term and long-term benefit in patients
with CIDP.
70 are found in about one-half of patients
with CIDP.